Skip to main content

Table 2 Characteristics of participants evaluated for chloroquine and lumefantrine ex vivo susceptibility assay

From: Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda

Characteristic2013
(N = 18)
2014
(N = 49)
2015
(N = 69)
2016
(N = 24)
2017
(N = 70)
2018
(N = 33)
Median age, years
(IQR)
5.0
(2.3, 7.3)
3.4
(2.0, 5.8)
4.6
(2.4, 4.8)
3.1
(2.0, 5.5)
2.5
(1.1, 3.8)
3.5
(1.0, 4.7)
Gender (male/female)8/1028/2130/3814/1033/3717/16
Clinical findings (n, %)
 Muscle or joint achesND3 (6.1)3 (4.4)2 (8.3)1 (1.4)3 (9.1)
 HeadacheND6 (12.2)8 (11.6)3 (12.5)5 (7.1)8 (24.2)
 AnorexiaND11 (22.5)7 (10.1)1 (4.2)5 (7.1)12 (36.4)
 Nausea/vomitingND9 (18.4)17 (24.6)11 (45.8)20 (28.6)17 (51.5)
 Abdominal painND6 (12.2)7 (10.1)03 (4.3)0
 DiarrhoeaND5 (10.2)6 (8.7)5 (21.0)7 (10.0)5 (15.2)
 CoughND18 (37.0)10 (14.5)6 (25.0)21 (30.0)28 (84.9)
 ConvulsionsND1 (2.0)1 (1.5)2 (8.3)3 (4.3)2 (6.1)
 JaundiceND2 (4.1)0000
 Temperature, °C
(IQR)
37.8
(37.4, 38.6)
38.1
(37.2, 39.0)
38.0
(37.5, 39.0)
37.7
(37.5, 39.3)
38.8
(37.8, 39.4)
38.5
(37.9, 38.9)
Laboratory findings
 Haemoglobin, g/dL
(Range)
ND10.6
(6.3–13.1)
NDND12.7
(11.2–14.1)
10.5
(9.3–11.6)
 Parasitaemia*, %
(IQR)
0.2
(0.1, 0.5)
1.0
(0.2, 2.6)
2.1
(0.7, 4.8)
2.1
(1.3, 3.3)
3.5
(2.4, 6.0)
2.0
(1.5, 2.8)
  1. ND not done, IQR inter quartile range
  2. * Significant differences were observed between studied year (p-value = 3.9 × 10−15, Kruskal–Wallis test)